Table 3.
The simulated AUC24h of polymyxin B on day four based on the final population pharmacokinetic model.
| Maintenance dose | CrCL (ml/min) | AUC24h (mg·h/L) | Css,avg (mg/L) | ||||
|---|---|---|---|---|---|---|---|
| P5 | P50 | P95 | P5 | P50 | P95 | ||
| 50 mg, q12h | 31.3 | 36.93 | 87.20 | 192.19 | 1.54 | 3.63 | 8.01 |
| 105.9 | 23.85 | 53.33 | 118.77 | 0.99 | 2.22 | 4.95 | |
| 315.2 | 15.54 | 37.92 | 84.49 | 0.65 | 1.58 | 3.52 | |
| 75 mg, q12h | 31.3 | 56.60 | 128.58 | 295.12 | 2.36 | 5.36 | 12.30 |
| 105.9 | 35.15 | 82.04 | 180.81 | 1.46 | 3.42 | 7.53 | |
| 315.2 | 22.46 | 53.60 | 121.32 | 0.94 | 2.23 | 5.06 | |
| 100 mg, q12h | 31.3 | 75.39 | 167.90 | 364.58 | 3.14 | 7.00 | 15.19 |
| 105.9 | 49.23 | 108.57 | 247.01 | 2.05 | 4.52 | 10.29 | |
| 315.2 | 30.29 | 71.91 | 167.40 | 1.26 | 3.00 | 6.98 | |
AUC24h, area under the plasma concentration-time curve over 24 hours; P5, 5th percentile; P50, 50th percentile; P95, 95th percentile; q12h, every 12 hours.